Kaditic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kaditic

Quick Facts

Property Description
Active ingredient Diclofenac (typically as Sodium salt)
Form Tablets, Injection Solution, Suppositories, Gel, Eye Drops
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common therapeutic use Relief of pain, inflammation, and fever
Origin Synthetic Phenylacetic acid derivative

What Type of Medicine is Kaditic?

Kaditic is a medicinal preparation defined by its core active ingredient, Diclofenac, which is typically formulated as Diclofenac sodium. It is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a major therapeutic category of potent anti-inflammatory and pain-relieving agents. This classification is clinically recognized due to the substance's established efficacy in modulating pain pathways. Diclofenac is a recognized synthetic compound belonging to the phenylacetic acid derivatives. As a single-ingredient, non-narcotic analgesic, Kaditic is primarily intended for prescription use, targeting physiological responses related to pain and inflammation across the body.

Composition, Forms, and General Therapeutic Purpose

The fundamental therapeutic purpose of Kaditic is to provide substantial symptomatic relief through its core anti-inflammatory, analgesic, and antipyretic effects. These actions are achieved by the active substance’s core mechanism as a cyclooxygenase (COX) inhibitor, which limits the production of inflammatory prostaglandins. To accommodate the requirement for both systemic and local effects, Diclofenac sodium is incorporated into various dosage forms, including enteric-coated tablets for oral systemic delivery, solution for injection for intramuscular systemic use, and localized preparations such as suppositories, topical gels, and eye drops. The availability of both systemic and specific local preparations is a differentiating factor, allowing medical professionals flexibility in managing conditions such as acute joint inflammation or post-operative discomfort.

Regulatory References

  1. National Cancer Institute (NCI Drug Dictionary)

What side effects are possible with Kaditic?

Official Safety Classifications and Potential Adverse Effects

The safety profile of Kaditic (Diclofenac) is documented in official regulatory labeling and is characterized by possible adverse reactions across several major organ systems. Adverse reactions are classified by their observed frequency in regulatory documents.

Commonly Documented Adverse Reactions

The most commonly reported adverse reactions typically involve the Gastrointestinal System, including nausea, vomiting, diarrhea, dyspepsia, abdominal pain, and flatulence. Reactions affecting the Nervous System such as headache and dizziness, as well as rash and elevated liver enzyme levels (transaminases), are also frequently documented in regulatory texts.

Serious Adverse Reaction Warnings

Official labeling includes serious warnings for rare but potentially fatal events:

  • Serious Cardiovascular Thrombotic Events: Diclofenac is associated with an increased risk of myocardial infarction (heart attack) and stroke. This risk may increase with the duration of use and has been observed most consistently with higher doses.
  • Serious Gastrointestinal Events: There is a documented risk of bleeding, ulceration, and perforation of the stomach or intestines. These serious events can occur at any time during use and may happen without warning symptoms.
  • Hepatobiliary and Skin Risks: Rare but severe adverse reactions include liver failure (e.g., fulminant hepatitis) and serious skin reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Population-Specific Safety Considerations

Regulatory restrictions specify increased caution or contraindication for certain groups:

  • Cardiovascular Conditions: Systemic use is contraindicated in patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, or congestive heart failure (NYHA classification II–IV).
  • Elderly Patients: This population is at greater risk for the serious consequences of gastrointestinal bleeding and perforation.
  • Pregnancy: Use is contraindicated in the last trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Diclofenac (Kaditic) is characterized by a range of signs primarily affecting the gastrointestinal (GI) and central nervous systems (CNS). Common manifestations listed in regulatory documents include nausea, vomiting, epigastric pain, diarrhea, headache, and drowsiness. Overdose may also present with CNS effects such as lethargy, confusion, and tinnitus.

In cases of significant exposure, severe, potentially life-threatening outcomes are officially documented, including acute renal failure, seizures, coma, and severe gastrointestinal bleeding. Hypertension and respiratory depression are also noted as possible severe effects. Regulatory documents indicate that elderly patients are particularly at risk, as GI bleeding and perforation following overdose can have more serious consequences.

Urgent Medical Action

Official prescribing information mandates that individuals seek medical help right away or contact a poison control center immediately if an overdose is suspected or has occurred. Since no specific antidote is known for Diclofenac overdose, management consists solely of symptomatic and supportive care. Decontamination procedures such as administering activated charcoal (within four hours of ingestion) or gastric lavage may be considered by medical professionals. Clearance procedures like hemodialysis are explicitly stated in labeling as unproven or not useful due to the drug's high protein binding.

Therapeutic Uses of Kaditic

Therapeutic Indications

Kaditic is a medication utilized in the management of specific conditions characterized by inflammation and pain. Its primary applications involve the treatment of acute and chronic musculoskeletal disorders and certain types of joint inflammation.

Main Uses

  • Rheumatoid Arthritis: Kaditic is used to address the chronic inflammation of the joints associated with this autoimmune condition, helping to manage the underlying swelling and discomfort.
  • Osteoarthritis: It is indicated for the symptomatic relief of degenerative joint disease, focusing on the pain and stiffness resulting from the breakdown of joint cartilage.
  • Ankylosing Spondylitis: The medication is utilized to treat inflammation affecting the spine and large joints, characteristic of this long-term condition.
  • Acute Musculoskeletal Trauma: It is applied in the short-term management of acute pain and inflammation resulting from sprains, strains, or other soft tissue injuries.

Benefits and Clinical Effects

Kaditic functions by inhibiting specific enzymes in the body that are responsible for the production of prostaglandins. Prostaglandins are chemical mediators that play a central role in the development of pain, fever, and inflammation.

By reducing the levels of these mediators, the medication provides the following clinical benefits:

  • Reduction of Inflammation: It assists in decreasing the physical swelling and redness in affected tissues or joints.
  • Pain Management: It provides analgesic effects by raising the threshold for pain signals in the peripheral nervous system.
  • Improvement in Mobility: By alleviating stiffness and discomfort, Kaditic helps restore functional movement in patients with chronic joint conditions.
  • Fever Reduction: In certain clinical contexts, the medication may be used to lower elevated body temperatures associated with inflammatory processes.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Kaditic — Official Regulatory Information

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults (≥18 years); Pediatric patients aged ≥12 years for certain oral formulations.
Populations for whom use is contraindicated History of Hypersensitivity to Diclofenac or any NSAID (e.g., aspirin-induced asthma); In the setting of Coronary Artery Bypass Graft (CABG) surgery; Last trimester of pregnancy (≥30 weeks gestation) [Source 1.1].

Age-related Eligibility Rules

Safety and efficacy are not established for most systemic forms in children under 12 years of age. Older adults require cautious use at the lowest effective dosage due to a higher risk of serious gastrointestinal events [Source 1.4].

Condition-specific Eligibility Rules

Kaditic is contraindicated in patients with active gastrointestinal ulceration, bleeding, or perforation, and in those with established severe heart failure (NYHA class II-IV) or ischemic heart disease [Source 1.2]. Use is not recommended in patients with advanced renal disease [Source 3.4].

Pregnancy and Lactation Eligibility Status

Use during pregnancy between sim20 and 30 weeks gestation should be limited to the lowest effective dose for the shortest duration. Use during breastfeeding is not recommended by some regulatory bodies [Source 2.3].

Connection to the overall eligibility profile

Regulatory documents define eligibility through strict exclusion criteria, classifying use as contraindicated for conditions like severe cardiovascular disease and late-stage pregnancy. Eligibility is also restricted based on age thresholds and the status of pre-existing conditions like hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information documents a number of interactions for Kaditic (diclofenac) that primarily involve either an increased risk of serious adverse effects or pharmacokinetic alterations affecting drug concentrations.

Do Not Combine / Use with Caution Combinations

Interacting Product Category Official Regulatory Constraint / Condition
Other NSAIDs / Analgesic Aspirin Concomitant use with other non-steroidal anti-inflammatory drugs (NSAIDs), including other diclofenac products, is generally not recommended due to increased cumulative risk of gastrointestinal (GI) adverse events.
Anticoagulants and Antiplatelet Agents Requires monitoring for bleeding due to additive effects on hemostasis, including when co-administered with SSRIs or SNRIs (Selective Serotonin/Norepinephrine Reuptake Inhibitors).
ACE Inhibitors / ARBs / Diuretics May diminish the antihypertensive or diuretic effect; in elderly or volume-depleted patients, co-administration requires monitoring for deterioration of renal function.
Specific Agents Monitoring of serum concentrations is required when used with Lithium or Digoxin due to the potential for increased systemic exposure. Use with Methotrexate requires caution due to potential for elevated plasma levels.

Diclofenac is primarily metabolized by CYP2C9; therefore, co-administration with strong CYP2C9 inhibitors can increase diclofenac exposure, and co-administration with CYP2C9 inducers can decrease it. These interactions dictate constraints on co-administration to manage the risk of adverse events and maintain therapeutic effectiveness, according to official governmental documents.

Mechanism of Action

The Mechanistic Action of Kaditic

Kaditic (Diclofenac) exerts its action primarily by modulating enzyme systems responsible for eicosanoid synthesis and secondarily by affecting peripheral nerve impulse conduction. The central mechanism involves the preferential competitive inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. This enzyme is activated in response to tissue damage and converts Arachidonic acid into pro-inflammatory Prostaglandins. This molecular blockade modifies the early steps of the Arachidonic Acid Cascade, thereby reducing the chemical signals that sensitize nociceptors and mediate increased vascular permeability. This mechanism results in a modulation of excessive inflammatory and nociceptive signaling.

The drug's mechanism also extends to the central nervous system; Prostaglandin synthesis inhibition in the hypothalamus supports the regulation of the core body temperature set point. Furthermore, a non-enzyme-related action involves the blocking of voltage-dependent sodium channels in sensory neurons. This secondary effect restricts the electrical transmission of nerve impulses along the nerve fiber, complementing the core enzyme inhibition. The interplay between peripheral enzyme blockade and central pathway modulation results in a modulation of these overactive physiological processes.

Dosage and Administration Information

Kaditic, as a diclofenac preparation, is administered across multiple official routes, including oral (tablets, capsules, powder), topical (gel, solution), rectal, and parenteral (injection) delivery.

The overarching principle of use is to employ the lowest effective dosage for the shortest duration necessary for administration. Standard systemic adult dosing typically ranges from 75 mg to 150 mg daily, administered in two or three divided doses; the maximum daily systemic dose is generally restricted to 150 mg.

Administration varies significantly by dosage form. Delayed-release and extended-release tablets must be swallowed whole and must not be crushed, chewed, or divided. Certain fast-acting oral forms, such as capsules or powder for oral solution, are specifically instructed to be taken on an empty stomach to ensure proper absorption. Conversely, other oral forms may be taken without regard to meals.

For special populations, official instructions recommend caution. Older adults should typically begin treatment at the lowest effective dosage. Patients with established renal or hepatic impairment may require careful consideration and the use of reduced doses. If a scheduled oral dose is missed, it should be taken when remembered, but if it is close to the time for the subsequent dose, the missed dose should be skipped; double doses are prohibited.

Recent Clinical Evidence

Kaditic: Recent Clinical Evidence

Summary of Initial Research Findings

Initial research efforts focused on characterizing the biological effects of the drug. Research examined the drug's properties through various in vitro and in vivo models.

  • Early Phase I/II Trials: Initial clinical trials focused on establishing the drug's maximum tolerated dose and assessing its absorption and elimination profile. These early-stage studies also began to characterize the drug's short-term profile related to observed adverse events.
  • Proof-of-Concept Studies: Small-scale trials explored the relationship between the drug's administration and subsequent changes in joint mobility assessments in participants with chronic joint discomfort. Research has explored the drug’s effect on pain perception and evaluated whether the drug was associated with changes in stiffness.
  • Pharmacodynamics: Studies examined the potential for long-term changes in inflammatory markers. The largest observed differences were documented in trials involving specific biomarkers (e.g., IL-6, TNF-alpha).

Clinical Efficacy Research

Research primarily focused on populations with chronic joint pain. Studies typically used a validated scale (e.g., VAS or WOMAC) to measure changes in participant-reported joint comfort and function over the study period.

Study 1: The XYLOS Trial (24 Weeks)

This randomized, placebo-controlled trial included 450 participants. Studies evaluated whether the drug influenced a primary endpoint defined as a 20% reduction in the WOMAC pain subscale score.

  • Results: Study results indicated that the primary endpoint was observed in more participants who received the investigational drug compared to those who received the placebo. Some studies included comparative arms, assessing outcomes against other treatments. The analysis noted that the duration of observed effect varied across the study population.

Study 2: Long-Term Follow-up (52 Weeks)

Long-term studies have monitored the drug's profile related to safety and efficacy over a one-year period. This open-label extension followed a subset of participants from the XYLOS Trial.

  • Safety Profile: The extended study duration included monitoring of adverse events, and the number of reported serious events was documented.
  • Study Administration: The study protocol utilized a specific formulation administered twice daily with food.

Safety and Tolerability Profile

Some clinical studies focused on the safety profile in individuals with mild to moderate kidney impairment, and the results reported that no dose adjustment was necessary for participants in the study setting. Research documented the characteristics of frequently reported adverse events across all studies.

Frequently Asked Questions (FAQ)

Common questions about Kaditic (FAQ)


Q: I saw someone say Kaditic makes them dizzy; is that a common side effect?

Yes, dizziness is one of the frequently reported adverse reactions documented in official product information for Kaditic. The regulatory texts classify this as a common side effect. Due to the potential for dizziness, official guidance describes considerations regarding activities like driving or operating machinery.


Q: Is it normal to feel a change in sleep patterns when starting Kaditic?

Official documents note that changes in sleep patterns have been reported as adverse reactions. These sometimes include specific events such as insomnia or nightmares. Changes in sleep patterns are events that may be reported to a healthcare professional.


Q: I use a daily vitamin; does Kaditic interact with common multivitamins?

Official sources primarily focus on interactions with other prescription and over-the-counter medicines. They generally note that there is insufficient data available from studies to confirm the safety of taking supplements, including common vitamins, alongside the medicine. Regulatory-aligned patient information describes the importance of reporting all supplements and vitamins to a healthcare professional.


Q: What happens if I accidentally take Kaditic with a medication that causes drowsiness?

Official documentation lists drowsiness and dizziness as potential adverse reactions to Kaditic. Official safety information notes that co-administration with other medicines that cause drowsiness or dizziness has the potential for additive effects on these adverse reactions.


Q: Does Kaditic work the same way for everyone who takes it?

Studies and official information indicate that the body's response to Kaditic can vary among individuals. Research, particularly in pharmacogenetics, has shown high variability in how the body processes and eliminates the active ingredient. This suggests that the medicine's effects and safety profile may differ from person to person.


Q: What are the most common reasons someone might be advised not to take Kaditic?

Official documents list several specific contraindications, which are conditions where the medicine should not be used. These include established severe heart failure, active stomach bleeding or ulceration, a history of allergic-type reactions to NSAIDs (like aspirin), and use in the setting of coronary artery bypass graft (CABG) surgery.


Q: What is the main difference between Kaditic and other medicines for the same condition?

Kaditic is formally characterized as a traditional Nonsteroidal Anti-inflammatory Drug (NSAID). Official research has examined its profile of effectiveness and potential safety risks in comparison to other medicines in the same class. The characteristics of the medicine, including its effectiveness and safety profile, have been examined across various studies, with specific findings described as varying depending on the dose and condition.


Q: Does Kaditic cause stomach issues, and what can be done about it?

Gastrointestinal issues, such as nausea and abdominal pain, are commonly documented adverse reactions. Official patient guidance, which is non-directive, suggests simple measures to manage common, mild issues. Measures such as eating simple, smaller, more frequent meals, and avoiding rich or spicy food are general non-directive comfort strategies mentioned in patient guidance.


Q: How long does it typically take before I might notice the effects of Kaditic?

Official data on the drug's absorption shows that for some fast-acting oral forms, the medication is absorbed quickly. Measurable drug levels may be observed in the bloodstream within approximately 10 minutes, with the drug reaching its highest concentration in the blood within about one hour in a fasted state.


Q: Are there any specific foods or drinks that should be avoided when using Kaditic?

While the official documentation generally specifies that taking the medicine with food does not change the total amount absorbed, it may delay how quickly the absorption process begins and reduce the peak concentration of the medicine in the blood. Specific lists of forbidden foods are not generally provided. Alcohol use is subject to warnings related to the risk of gastrointestinal adverse events, as documented in regulatory information.


Q: I heard Kaditic is a 'newer' drug; what kind of evidence supports its use?

Kaditic is characterized as a traditional Nonsteroidal Anti-inflammatory Drug (NSAID). Its use is supported by a body of clinical trials and research that evaluated its effect on pain and inflammation. The evidence includes studies that characterized its anti-inflammatory effects and clinical trials that compared its outcomes and safety profile to other similar medicines.


Q: I have allergies; are there common inactive ingredients in Kaditic I should know about?

The official product labeling for specific oral forms lists the active substance along with inactive ingredients. These non-therapeutic components may include common substances such as lactose, titanium dioxide, iron oxides, and various dyes used in the tablet coatings. An individual can review the official label to see the complete list for their specific formulation.


Q: Why do official sources sometimes use different names for the same drug, like Kaditic?

Official documents for the active ingredient (Diclofenac) confirm that it is marketed by various manufacturers under multiple different brand names across different regions and countries. This means that several different trade names may be used to refer to the same active ingredient.


Q: Are there specific symptoms that mean I should stop taking Kaditic immediately?

Official labeling describes the signs of a serious problem (e.g., internal bleeding, liver injury) as conditions for which contacting a healthcare professional or seeking emergency care is advised. These signs include symptoms of internal bleeding (such as bloody, black, or tar-like stools), signs of liver problems (like yellowing of the skin or eyes), or allergic-type reactions (such as rash combined with fever or swelling).


Q: Does Kaditic need to be taken at the exact same time every day?

Official patient instructions generally advise taking the medication as directed on the prescription label. This often includes a recommendation to take the doses at the same time every day to help maintain consistent levels of the medicine in the body.


Q: Are there any limitations on driving or operating machinery while taking Kaditic?

Due to the documented potential for central nervous system side effects, such as dizziness or feeling lightheaded, regulatory guidance describes considerations regarding driving, cycling, or operating tools or machinery.


Q: How long does Kaditic stay in your system after the last intake?

According to pharmacokinetic data in official drug references, the terminal half-life of the unchanged drug is approximately 2 hours. However, the apparent half-life, which accounts for the duration of the drug and its related breakdown products, is documented to be significantly longer.


Q: Is Kaditic known to affect mood or cause emotional changes?

Official adverse reaction listings document that changes in mood and mental state have been rarely reported. These types of reactions can include symptoms such as depression, confusion, irritability, and nervousness.


Q: Is Kaditic approved in other countries besides the one I'm in?

The active ingredient in Kaditic is subject to regulatory oversight by major governmental agencies worldwide. Regulatory guidance from bodies such as the European Medicines Agency (EMA) and agencies in the UK and other countries indicates widespread approval and use.


Q: Can Kaditic cause skin rashes or allergic reactions?

Official documentation notes that skin rashes are commonly reported. Furthermore, severe, sometimes fatal, allergic-type reactions (including anaphylaxis) and serious skin reactions like Stevens-Johnson Syndrome (SJS) have been reported and require immediate medical attention.


Q: How quickly does the body process Kaditic after it is taken?

Kaditic is processed (metabolized) primarily in the liver through specific enzyme systems. The drug and its breakdown products are then eliminated from the body through the kidneys in the urine and through bile. This process of metabolism helps to control how long the medicine remains active.


Q: Are there specific lifestyle factors, like smoking, that interact with Kaditic?

Official patient information sheets describe the importance of disclosing all lifestyle factors, including tobacco use, to a healthcare professional, as these may be relevant to the drug's overall safety and efficacy profile.


Q: What should I do if I suspect a severe interaction between Kaditic and another drug?

In the event of a suspected severe interaction or serious adverse reaction, official patient information describes this as a condition requiring immediate contact with a healthcare professional or emergency medical services.


Q: Can Kaditic be used to prevent a condition, or is it only for treatment?

Official indications for Kaditic state that its purpose is for the relief of pain and inflammation associated with various established conditions. Its listed uses focus on the symptomatic treatment of existing medical issues, not the prevention of a condition.


Q: What is the role of the inactive ingredients in Kaditic?

Inactive ingredients do not provide a therapeutic effect on the condition being treated. They serve a technical purpose, such as helping to stabilize the active ingredient, controlling its release into the body (for instance, through enteric or extended-release coatings), or forming the physical structure of the tablet or capsule.


Q: Does Kaditic have a risk of dependency or addiction?

Kaditic is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not designated as a controlled substance associated with abuse or dependency according to regulatory classification.


How should Kaditic be stored and disposed of?

The storage and disposal instructions for Kaditic (Diclofenac) are strictly defined by regulatory labeling to maintain product stability and ensure safety.

Storage Requirements

Kaditic must be stored at Controlled Room Temperature, typically 20 C to 25 C, and requires protection from light and excessive moisture. It is explicitly required to keep from freezing and not to store the product above the maximum temperature specified on the label. The medicine must remain in its original container and be kept tightly closed when not in use.

Safety and Disposal

Official labeling universally mandates the instruction to keep out of the sight and reach of children. Unused or expired Kaditic should be disposed of through a dedicated drug take-back program. If a take-back option is unavailable, regulatory guidance permits mixing the medicine with an unpalatable substance (like coffee grounds or litter) before sealing it and discarding it in the household trash. It should not be disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kaditic found in:

A-Z Index: